These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36681041)

  • 21. Does melatonin mediate the therapeutic effects of 5-HT reuptake inhibitors in obsessive compulsive disorder?
    Sandyk R
    Int J Neurosci; 1992; 64(1-4):221-3. PubMed ID: 1342043
    [No Abstract]   [Full Text] [Related]  

  • 22. Sertraline and obsessive compulsive disorder: new indication. Limited assessment.
    Prescrire Int; 2000 Aug; 9(48):112-3. PubMed ID: 11067720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors.
    Hollander E
    Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():75-87. PubMed ID: 9032004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obsessive-compulsive disorder in Tourette syndrome.
    Goodman WK; Storch EA; Geffken GR; Murphy TK
    J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbamazepine for serotonin reuptake inhibitor nonresponder case of obsessive compulsive disorder.
    Aggarwal A; Jain M; Garg A; Jiloha RC
    Indian J Med Sci; 2009 Oct; 63(10):468-9. PubMed ID: 19901487
    [No Abstract]   [Full Text] [Related]  

  • 27. [Obsessive-compulsive symptoms in schizophrenia: remission with anti-obsessive treatment].
    Payá González B; Crespo Facorro B; Sáenz Herrero M; Ayuso Gutiérrez JL
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(3):201-3. PubMed ID: 9717345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of obsessive-compulsive disorder in an adult].
    Kähkönen S; Holmberg N
    Duodecim; 2010; 126(11):1310-6. PubMed ID: 20681354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venlafaxine in treatment resistant obsessive-compulsive disorder.
    Narayanaswamy JC; Viswanath B; Cherian AV; Math SB; Reddy YC
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E44-5. PubMed ID: 25093787
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 31. Obsessive-compulsive disorder due to neuroacanthocytosis treated with citalopram. A case report.
    Habermeyer B; Fuhr P; Hiss B; Alber C; Müller-Spahn F
    Pharmacopsychiatry; 2006 Sep; 39(5):193-4. PubMed ID: 16944412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.
    Zai G; Brandl EJ; Müller DJ; Richter MA; Kennedy JL
    Pharmacogenomics; 2014 Jun; 15(8):1147-57. PubMed ID: 25084207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
    Humble M; Bejerot S; Bergqvist PB; Bengtsson F
    Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-selective effects of selective serotonin reuptake inhibitors.
    Zurowski B; Kordon A; Wahl K; Hohagen F
    Biol Psychiatry; 2008 Jan; 63(1):e5; author reply e7. PubMed ID: 17693390
    [No Abstract]   [Full Text] [Related]  

  • 37. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].
    Okamoto Y
    Seishin Shinkeigaku Zasshi; 2011; 113(1):36-44. PubMed ID: 21404630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of pharmacologic treatments for obsessive-compulsive disorder.
    Kaplan A; Hollander E
    Psychiatr Serv; 2003 Aug; 54(8):1111-8. PubMed ID: 12883138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.
    Stein DJ; Koen N; Fineberg N; Fontenelle LF; Matsunaga H; Osser D; Simpson HB
    Curr Psychiatry Rep; 2012 Jun; 14(3):211-9. PubMed ID: 22527872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.